Poseida Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
337
- Stock Symbol
-
PSTX
- Investments
-
1
- Share Price
-
$2.88
- (As of Monday Closing)
Poseida Therapeutics General Information
Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Contact Information
Website
www.poseida.comCorporate Office
- 9390 Towne Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 9390 Towne Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Poseida Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.88 | $2.74 | $1.83 - $4.27 | $281M | 97.1M | 428K | -$1.19 |
Poseida Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 169,031 | 168,721 | 267,180 | 287,985 |
| Revenue | 88,462 | 64,703 | 130,492 | 31,238 |
| EBITDA | (98,042) | (109,038) | (51,916) | (117,064) |
| Net Income | (112,772) | (123,430) | (64,002) | (124,974) |
| Total Assets | 298,686 | 273,885 | 351,837 | 269,309 |
| Total Debt | 83,653 | 85,423 | 88,752 | 61,198 |
Poseida Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Poseida Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Poseida Therapeutics Comparisons
Industry
Financing
Details
000 00
000000
Poseida Therapeutics Competitors (49)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vor Biopharma | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | 00 | 00000 | 000000000 | 00000 |
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
| Mustang Bio | Corporation | Worcester, MA | 00 | 00000 | 000000000 | 00000 |
| Valerio Therapeutics | Formerly VC-backed | Paris, France | 00 | 00000 | 000000000 | 00000 |
Poseida Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Poseida Therapeutics Patents
Poseida Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023210287-A1 | Compositions and methods for delivery of nucleic acids | Pending | 21-Jan-2022 | ||
| CA-3234642-A1 | Transposases and uses thereof | Pending | 04-Oct-2021 | 0000000000 | |
| AU-2022360244-A1 | Transposon compositions and methods of use thereof | Pending | 04-Oct-2021 | 000000000 | |
| CA-3233506-A1 | Transposon compositions and methods of use thereof | Pending | 04-Oct-2021 | 000000000 | |
| AU-2022358729-A1 | Transposases and uses thereof | Pending | 04-Oct-2021 | C12N9/1241 |
Poseida Therapeutics Executive Team (18)
| Name | Title | Board Seat |
|---|---|---|
| Kristin Yarema Ph.D | President, Chief Executive Officer & Board Member | |
| Johanna Mylet | Chief Financial Officer | |
| Loren Wagner | Chief Operating Officer, Operations | |
| Kristin Martin | Chief People Officer & Chief Administrative Officer | |
| Devon Shedlock Ph.D | Chief Scientific Officer, Cell Therapy |
Poseida Therapeutics Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Charles Baum Ph.D | Self | Board Member | 000 0000 |
| Cynthia Collins | Self | Board Member | 000 0000 |
| John Schmid | Self | Board Member | 000 0000 |
| Kristin Yarema Ph.D | Poseida Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 |
| Mark Gergen JD | Self | Chairman & Board Member | 000 0000 |
Poseida Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Poseida Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Poseida Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vindico Pharma | 10-Oct-2016 | 0000000000 | 0000 | Drug Discovery |
Poseida Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 27, 2023
27.42 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
Poseida Therapeutics FAQs
-
When was Poseida Therapeutics founded?
Poseida Therapeutics was founded in 2014.
-
Who is the CEO of Poseida Therapeutics?
Kristin Yarema Ph.D is the CEO of Poseida Therapeutics.
-
Where is Poseida Therapeutics headquartered?
Poseida Therapeutics is headquartered in San Diego, CA.
-
What is the size of Poseida Therapeutics?
Poseida Therapeutics has 337 total employees.
-
What industry is Poseida Therapeutics in?
Poseida Therapeutics’s primary industry is Drug Discovery.
-
Is Poseida Therapeutics a private or public company?
Poseida Therapeutics is a Public company.
-
What is Poseida Therapeutics’s stock symbol?
The ticker symbol for Poseida Therapeutics is PSTX.
-
What is the current stock price of Poseida Therapeutics?
As of 09-Sep-2024 the stock price of Poseida Therapeutics is $2.88.
-
What is the current market cap of Poseida Therapeutics?
The current market capitalization of Poseida Therapeutics is $281M.
-
What is Poseida Therapeutics’s current revenue?
The trailing twelve month revenue for Poseida Therapeutics is $88.5M.
-
Who are Poseida Therapeutics’s competitors?
Vor Biopharma, Carisma Therapeutics, Fate Therapeutics, Mustang Bio, and Valerio Therapeutics are some of the 49 competitors of Poseida Therapeutics.
-
What is Poseida Therapeutics’s annual earnings per share (EPS)?
Poseida Therapeutics’s EPS for 12 months was -$1.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
